Barrington raised the firm’s price target on Haemonetics (HAE) to $93 from$90 and keeps an Outperform rating on the shares after the company announced that it had acquired Vivasure Medical Limited, an Ireland-based developer of advanced polymer implants and delivery systems. The firm is increasing its price target based on a positive view of the Vivasure transaction, the analyst tells investors. Claim 70% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time, market-moving b ...